Project UpdateMay 26, 2026, 08:02 AM
Calidi to Present RedTail Platform Preclinical Data at ASCO 2026
AI Summary
Calidi Biotherapeutics announced that two abstracts highlighting its proprietary RedTail platform have been accepted for online publication at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will present preclinical data on its lead program, CLD-401, a systemically delivered virotherapy, and expects to file an IND for it by the end of 2026. Additionally, preclinical data on CLD-501, an in situ T-cell engager, will be presented, showcasing the platform's ability to deliver genetic medicines to metastatic sites.
Key Highlights
- Calidi Biotherapeutics to present preclinical data on its RedTail platform at the 2026 ASCO Annual Meeting.
- Two abstracts showcasing the RedTail platform, including CLD-401 and CLD-501, accepted for online publication.
- CLD-401 is a systemically delivered virotherapy designed to express IL-15 superagonist in tumors.
- Company expects to file an Investigational New Drug (IND) application for CLD-401 by the end of 2026.
- CLD-501 is a systemically delivered virotherapy expressing a TROP-2 T-cell engager and IL-15 SA.
- Data demonstrates RedTail platform's potential for systemic delivery of genetic medicine to metastatic sites.
- The platform aims to remodel the tumor microenvironment and enable high-level expression of therapeutic payloads.
Price Impact
More from CLDI